vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Wingstop Inc. (WING). Click either name above to swap in a different company.
Wingstop Inc. is the larger business by last-quarter revenue ($183.7M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). Wingstop Inc. runs the higher net margin — 16.3% vs 1.6%, a 14.6% gap on every dollar of revenue. On growth, Wingstop Inc. posted the faster year-over-year revenue change (7.4% vs 5.0%). Over the past eight quarters, Wingstop Inc.'s revenue compounded faster (8.6% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Wingstop Inc. is an American international fast food chain that primarily sells buffalo wings. Wingstop locations are decorated with a 1930s and 1940s pre-jet aviation theme.
PCRX vs WING — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $183.7M |
| Net Profit | $2.9M | $29.9M |
| Gross Margin | — | 86.5% |
| Operating Margin | 3.9% | 27.4% |
| Net Margin | 1.6% | 16.3% |
| Revenue YoY | 5.0% | 7.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.07 | $1.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $183.7M | ||
| Q4 25 | $196.9M | $175.7M | ||
| Q3 25 | $179.5M | $175.7M | ||
| Q2 25 | $181.1M | $174.3M | ||
| Q1 25 | $168.9M | $171.1M | ||
| Q4 24 | $187.3M | $161.8M | ||
| Q3 24 | $168.6M | $162.5M | ||
| Q2 24 | $178.0M | $155.7M |
| Q1 26 | $2.9M | $29.9M | ||
| Q4 25 | — | $26.8M | ||
| Q3 25 | $5.4M | $28.5M | ||
| Q2 25 | $-4.8M | $26.8M | ||
| Q1 25 | $4.8M | $92.3M | ||
| Q4 24 | — | $26.8M | ||
| Q3 24 | $-143.5M | $25.7M | ||
| Q2 24 | $18.9M | $27.5M |
| Q1 26 | — | 86.5% | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | 85.6% | ||
| Q3 24 | 76.9% | 85.0% | ||
| Q2 24 | 75.1% | 85.4% |
| Q1 26 | 3.9% | 27.4% | ||
| Q4 25 | 1.2% | 26.7% | ||
| Q3 25 | 3.5% | 27.9% | ||
| Q2 25 | 4.7% | 25.9% | ||
| Q1 25 | 1.2% | 22.4% | ||
| Q4 24 | 13.2% | 25.9% | ||
| Q3 24 | -82.8% | 24.5% | ||
| Q2 24 | 15.9% | 26.5% |
| Q1 26 | 1.6% | 16.3% | ||
| Q4 25 | — | 15.2% | ||
| Q3 25 | 3.0% | 16.2% | ||
| Q2 25 | -2.7% | 15.4% | ||
| Q1 25 | 2.8% | 53.9% | ||
| Q4 24 | — | 16.5% | ||
| Q3 24 | -85.1% | 15.8% | ||
| Q2 24 | 10.6% | 17.7% |
| Q1 26 | $0.07 | $1.08 | ||
| Q4 25 | $0.05 | $0.99 | ||
| Q3 25 | $0.12 | $1.02 | ||
| Q2 25 | $-0.11 | $0.96 | ||
| Q1 25 | $0.10 | $3.24 | ||
| Q4 24 | $0.38 | $0.91 | ||
| Q3 24 | $-3.11 | $0.88 | ||
| Q2 24 | $0.39 | $0.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $128.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | — |
| Total Assets | $1.2B | $648.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $128.8M | ||
| Q4 25 | $238.4M | $196.6M | ||
| Q3 25 | $246.3M | $237.6M | ||
| Q2 25 | $445.9M | $227.9M | ||
| Q1 25 | $493.6M | $251.4M | ||
| Q4 24 | $484.6M | $315.9M | ||
| Q3 24 | $453.8M | $84.0M | ||
| Q2 24 | $404.2M | $96.7M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $1.2B | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-736.8M | ||
| Q3 25 | $727.2M | $-702.6M | ||
| Q2 25 | $757.8M | $-686.0M | ||
| Q1 25 | $798.5M | $-715.0M | ||
| Q4 24 | $778.3M | $-675.6M | ||
| Q3 24 | $749.6M | $-447.5M | ||
| Q2 24 | $879.3M | $-437.5M |
| Q1 26 | $1.2B | $648.9M | ||
| Q4 25 | $1.3B | $693.4M | ||
| Q3 25 | $1.3B | $721.0M | ||
| Q2 25 | $1.5B | $708.3M | ||
| Q1 25 | $1.6B | $696.8M | ||
| Q4 24 | $1.6B | $716.2M | ||
| Q3 24 | $1.5B | $484.8M | ||
| Q2 24 | $1.6B | $451.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
WING
| Royalty revenue, franchise fees and other | $87.5M | 48% |
| Advertising fees | $63.3M | 34% |
| Company-owned restaurant sales | $33.0M | 18% |
